Daiichi Sankyo Inks Deal For Lilly’s Evista
This article was originally published in PharmAsia News
Executive Summary
Munich, Germany-based Daiichi Sankyo Europe GmbH announced that its Japanese parent Daiichi Sankyo Group has purchased European rights to the osteoporosis medication Evista (raloxifene)from Lilly. Daiichi plans to expand marketing of Evista from eight European countries to 34. The Japanese company predicts growth in sales from €20 million currently to approximately €80 million. (Click here for more - Japanese language